BioMerieux forecasts strong growth for 2017 following successful 2016

BioMerieux has announced its finalised financial results for 2016, confirming a strong growth performance for the company during the year.

The company generated 2.1 billion euros (1.8 billion pounds) during the 12 months, representing a 7.1 percent year-on-year increase, or 9.6 percent at constant exchange rates and scope of consolidation.

This performance was attributed to the strength of the firm's results in North America and in molecular biology, with the FilmArray brand delivering a particularly robust performance.

With earnings per share also up 62 percent year on year, BioMerieux has predicted organic growth in sales of between eight and nine percent in 2017, although foreign exchange volatility could have an impact on the bottom line.

Alexandre Merieux, chief executive officer of BioMerieux, said: "BioMerieux will step up its research and innovation spending to sharpen its strategic focus on molecular biology and clinical and industrial microbiology, providing a solid foundation for the group's expansion going forward."

With over 20 years of experience within the science market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current science roles we have available, you can search for the latest job roles, register your details, or contact the team today.